Live Updates: COVID-19 Cases
  • World 30,493,112
    World
    Confirmed: 30,493,112
    Active: 7,371,305
    Recovered: 22,169,507
    Death: 952,300
  • USA 6,892,468
    USA
    Confirmed: 6,892,468
    Active: 2,530,620
    Recovered: 4,159,285
    Death: 202,563
  • India 5,247,627
    India
    Confirmed: 5,247,627
    Active: 1,019,663
    Recovered: 4,143,247
    Death: 84,717
  • Brazil 4,457,443
    Brazil
    Confirmed: 4,457,443
    Active: 569,330
    Recovered: 3,753,082
    Death: 135,031
  • Russia 1,091,186
    Russia
    Confirmed: 1,091,186
    Active: 170,784
    Recovered: 901,207
    Death: 19,195
  • Peru 750,098
    Peru
    Confirmed: 750,098
    Active: 124,439
    Recovered: 594,513
    Death: 31,146
  • Mexico 684,113
    Mexico
    Confirmed: 684,113
    Active: 123,518
    Recovered: 488,416
    Death: 72,179
  • South Africa 655,572
    South Africa
    Confirmed: 655,572
    Active: 54,497
    Recovered: 585,303
    Death: 15,772
  • Spain 654,637
    Spain
    Confirmed: 654,637
    Active: 624,232
    Recovered: ?
    Death: 30,405
  • Chile 442,827
    Chile
    Confirmed: 442,827
    Active: 14,647
    Recovered: 415,981
    Death: 12,199
  • Iran 416,198
    Iran
    Confirmed: 416,198
    Active: 36,741
    Recovered: 355,505
    Death: 23,952
  • France 415,481
    France
    Confirmed: 415,481
    Active: 293,546
    Recovered: 90,840
    Death: 31,095
  • UK 385,936
    UK
    Confirmed: 385,936
    Active: 344,204
    Recovered: ?
    Death: 41,732
  • Bangladesh 345,805
    Bangladesh
    Confirmed: 345,805
    Active: 88,589
    Recovered: 252,335
    Death: 4,881
  • Saudi Arabia 328,720
    Saudi Arabia
    Confirmed: 328,720
    Active: 15,938
    Recovered: 308,352
    Death: 4,430
  • Pakistan 304,386
    Pakistan
    Confirmed: 304,386
    Active: 6,295
    Recovered: 291,683
    Death: 6,408
  • Turkey 299,810
    Turkey
    Confirmed: 299,810
    Active: 27,628
    Recovered: 264,805
    Death: 7,377
  • Italy 294,932
    Italy
    Confirmed: 294,932
    Active: 42,457
    Recovered: 216,807
    Death: 35,668
  • Germany 270,653
    Germany
    Confirmed: 270,653
    Active: 19,890
    Recovered: 241,300
    Death: 9,463
  • Canada 141,565
    Canada
    Confirmed: 141,565
    Active: 8,852
    Recovered: 123,512
    Death: 9,201
  • Netherlands 90,047
    Netherlands
    Confirmed: 90,047
    Active: 83,774
    Recovered: ?
    Death: 6,273
  • China 85,255
    China
    Confirmed: 85,255
    Active: 165
    Recovered: 80,456
    Death: 4,634
  • Australia 26,861
    Australia
    Confirmed: 26,861
    Active: 2,169
    Recovered: 23,855
    Death: 837
  • S. Korea 22,783
    S. Korea
    Confirmed: 22,783
    Active: 2,635
    Recovered: 19,771
    Death: 377
  • New Zealand 1,809
    New Zealand
    Confirmed: 1,809
    Active: 70
    Recovered: 1,714
    Death: 25

Scientists use AI to identify hundreds of COVID-19 drug candidates

Author at TechGenyz Health
SARS
An image of SARS virus

A team led by an Indian-origin scientist has used artificial intelligence (AI) to identify hundreds of new potential drugs that could help treat COVID-19, the disease caused by the novel coronavirus, or SARS-CoV-2.

“There is an urgent need to identify effective drugs that treat or prevent COVID-19,” said Anandasankar Ray, a professor at the University of California, Riverside in the US.

We have developed a drug discovery pipeline that identified several candidates.- Ray, who led the research published in the journal Heliyon.

The drug discovery pipeline is a type of computational strategy linked to AI — a computer algorithm that learns to predict activity through trial and error, improving over time.

With no clear end in sight, the COVID-19 pandemic has disrupted lives, strained health care systems, and weakened economies, the researchers said.

Efforts to repurpose drugs, such as Remdesivir, have achieved some success. A vaccine for the SARS-CoV-2 virus could be months away, though it is not guaranteed, they said.

“As a result, drug candidate pipelines, such as the one we developed, are extremely important to pursue as a first step towards the systematic discovery of new drugs for treating COVID-19,” Ray said.

“Existing FDA-approved drugs that target one or more human proteins important for viral entry and replication are currently a high priority for repurposing as new COVID-19 drugs,” he said.

Ray said the demand is high for additional drugs or small molecules that can interfere with both entry and replication of SARS-CoV-2 in the body, adding “our drug discovery pipeline can help.”

Joel Kowalewski, a graduate student in Ray’s lab, used small numbers of previously known ligands for 65 human proteins that are known to interact with SARS-CoV-2 proteins.

He generated machine learning models for each of the human proteins.

These models are trained to identify new small molecule inhibitors and activators the ligands simply from their 3D structures.- Kowalewski.

The researchers were thus able to create a database of chemicals whose structures were predicted as interactors of the 65 protein targets. They also evaluated the chemicals for safety.

“The 65 protein targets are quite diverse and are implicated in many additional diseases as well, including cancers,” Kowalewski said.

Ray and Kowalewski used their machine learning models to screen more than 10 million commercially available small molecules from a database comprised of 200 million chemicals.

They identified the best-in-class hits for the 65 human proteins that interact with SARS-CoV-2 proteins.

The researchers identified compounds among the hits that are already FDA approved, such as drugs and compounds used in food.

They also used their models to compute toxicity, which helped them reject potentially toxic candidates.

This helped them prioritize the chemicals that were predicted to interact with SARS-CoV-2 targets.

The method allowed the researchers to not only identify the highest scoring candidates with significant activity against a single human protein target but also find a few chemicals that were predicted to inhibit two or more human protein targets.

“Compounds I am most excited to pursue are those predicted to be volatile, setting up the unusual possibility of inhaled therapeutics,” Ray added.

Career

Subscribe